Harvard Bioscience
(HBIO)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2004 | 12-2003 | 12-2002 | 12-2001 | 12-2000 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 2,329 | 4,260 | 737 | -5,208 | -49,870 |
| Depreciation Amortization | 6,346 | 5,289 | 3,010 | 2,971 | 1,490 |
| Income taxes - deferred | -918 | 119 | -555 | 194 | 928 |
| Accounts receivable | 1,382 | -3,056 | -3,716 | -691 | -737 |
| Accounts payable and accrued liabilities | -587 | -176 | -629 | -48 | 325 |
| Other Working Capital | 3,448 | -8,170 | -5,212 | -2,158 | -1,963 |
| Other Operating Activity | -562 | 3,762 | 7,165 | 9,036 | 51,973 |
| Operating Cash Flow | $11,438 | $2,028 | $800 | $4,095 | $2,146 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -2,966 | -1,231 | -1,307 | -1,833 | -627 |
| Net Acquisitions | -7,082 | -21,149 | -10,736 | -17,984 | -4,032 |
| Other Investing Activity | -371 | -17 | -324 | -359 | -674 |
| Investing Cash Flow | $-10,419 | $-22,397 | $-12,367 | $-20,176 | $-5,332 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | N/A | 6,500 | N/A | N/A | 1,600 |
| Debt Issued | 6,950 | 12,489 | N/A | 4,326 | 2,000 |
| Debt Repayment | -3,611 | -707 | -3,745 | -507 | -7,859 |
| Common Stock Issued | 871 | 1,272 | 600 | 5,880 | 46,251 |
| Dividend Paid | N/A | N/A | N/A | N/A | -171 |
| Other Financing Activity | 0 | -6,500 | 0 | 0 | -5,300 |
| Financing Cash Flow | $4,210 | $13,054 | $-3,145 | $9,698 | $36,521 |
| Exchange Rate Effect | 415 | 225 | 640 | -49 | 87 |
| Beginning Cash Position | 8,223 | 15,313 | 29,385 | 35,817 | 2,396 |
| End Cash Position | 13,867 | 8,223 | 15,313 | 29,386 | 35,817 |
| Net Cash Flow | $5,644 | $-7,090 | $-14,072 | $-6,432 | $33,421 |
| Free Cash Flow | |||||
| Operating Cash Flow | 11,438 | 2,028 | 800 | 4,095 | 2,146 |
| Capital Expenditure | -3,011 | -1,349 | -1,307 | -1,839 | -630 |
| Free Cash Flow | 8,427 | 679 | -507 | 2,256 | 1,516 |